Upadacitinib, a selective Janus kinase 1 inhibitor, has demonstrated efficacy in moderate-to-severe inflammatory bowel disease (IBD). Although its safety profile has been well established, genitourinary adverse events have rarely been reported. We present the ... ...

请注册登录后继续浏览